Fifteen researchers from the Radboud University and Radboud university medical center have been awarded a Veni grant by NWO, the Netherlands Organisation for Scientific Research. These grants of up to €250,000 provide highly promising young scientists with the opportunity to further elaborate their own ideas during a period of three years.Nienke de Vries-Farrouh, theme Disorders of movement received a Veni grant for her project: "Bringing Parkinson care back home".
Nienke de Vries-Farrouh will study whether using a wearable sensor that automatically measures falls and physical activity offers relevant information about the functioning of patients with Parkinson’s disease. She also will investigate if patients and physiotherapists can use this teelmonitoring information to improve the quality of their medical decision making for individual patients.
15 Veni grants for Radboud researchers: more information in this link.
Related news items
Lowering cholesterol is not enough to reduce hyperactivity of the immune system14 June 2019
In Cell Metabolism, Siroon Bekkering, theme Vascular damage, and colleagues, provides a novel potential explanation for the residual cardiovascular risk, related to persistent activation of the immune system in patients with hypercholesterolemia who are treated with statins.read more
A personal touch of Johan van der Vlag13 June 2019
In order to promote interaction amongst colleagues within RIMLS, we have a ‘personal touch’ series setting employees in the spotlight. A light-hearted manner to learn about the colleagues you know and those you don’t. This week: Johan van der Vlag.read more
Peter van der Kraan new theme leader Inflammatory diseases13 June 2019
It is our pleasure to introduce Peter van der Kraan from the Dept. of Rheumatology, as the new leader of our theme Inflammatory diseases. As such he will be the successor of Irma Joosten who has done an outstanding job in the last years as theme leader, for which we thank her wholeheartedly.read more
Intake of a reduced dose of pazopanib with food the effect on pharmacokinetics, patient safety and preference13 June 2019
In Clinical Pharmacology & Therapeutics Floor Lubberman and colleagues showed that the intake of 600mg pazopanib with food resulted in a bioequivalent exposure and was preferred over a standard pazopanib dose without food.read more